Latest G protein Stories
Scientists have developed a small-molecule-inhibiting drug that in early laboratory cell tests stopped breast cancer cells from spreading and also promoted the growth of early nerve cells called neurites.
In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells’ response to light—and the development of night blindness, a rare disease that abolishes the ability to see in dim light.
Half the drugs used today target a single class of proteins – and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.
Three international teams of scientists, led by researchers at the University of California San Diego, University of Michigan and Stanford University, have published a trio of papers describing in unprecedented detail the structure and workings of G protein-coupled receptors (GPCRs), a large family of human proteins that are the target of one-third to one-half of modern drugs.
SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today the publication of research that uncovered a previously unknown role for a class of molecules that could lead to future advances in immunologic medicine.
G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development.
Unlike conventional methods, with the so-called optogenetics, the researchers are able to target one cell type.